Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Viloxazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 7/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 7/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 1.00 |
| ▸ | HTR2A | P28223 | 4/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.80 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.62 |
| ▸ | HRH1 | P35367 | 1/20 | 0.62 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.62 |
| ▸ | HTR3A | P46098 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | MLNR | O43193 | 1/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.57 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.57 |
| ▸ | HTR2C | P28335 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Viloxazine SCHEMBL29359040 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3HTR2AHTR2B | |
| (R)-Viloxazine SCHEMBL2524727 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3HTR2AHTR2B | |
| (R)-Viloxazine SCHEMBL30589854 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3HTR2AHTR2B | |
| (S)-Viloxazine SCHEMBL31126415 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3HTR2AHTR2B | |
| (S)-Viloxazine SCHEMBL2524730 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3HTR2AHTR2B | |
| (S)-Viloxazine SCHEMBL25394508 | 0.99 | SLC6A4 (0.97) | SLC6A4SLC6A2SLC6A3HTR2AHTR2B | |
| Viloxazine SCHEMBL29362568 | 0.99 | SLC6A4 (0.97) | SLC6A4SLC6A2SLC6A3HTR2AHTR2B | |
| (R)-Viloxazine SCHEMBL30439261 | 0.99 | SLC6A4 (0.97) | SLC6A4SLC6A2SLC6A3HTR2AHTR2B | |
| Viloxazine SCHEMBL300741 | 0.99 | SLC6A4 (0.97) | SLC6A4SLC6A2SLC6A3HTR2AHTR2B | |
| Viloxazine SCHEMBL1651391 | 0.97 | SLC6A4 (0.95) | SLC6A4SLC6A2SLC6A3HTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 8463 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115163-A1 | NOVEL TREATMENTS | 3Z EHF (IS) | 2026-04-30 | — | — | US | claimed |
| EP-4704826-A1 | COMPOSITIONS AND METHODS FOR TREATING POST-TRAUMATIC STRESS DISORDER | Yale University (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4704971-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| US-20260062395-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF VILOXAZINE AND OTHER 2-SUBSTITUTED MORPHOLINE DERIVATIVES | CURIA SPAIN S A U (ES) | 2026-03-05 | — | — | US | claimed |
| WO-2026044401-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING VILOXAZINE | APOTEX INC (CA) | 2026-03-05 | — | — | WO | claimed |
| US-20260001942-A1 | TREATMENT OF HEADACHE DISORDERS AND/OR PSYCHIATRIC SYMPTOMS USING ANTI-CGRP ANTIBODIES, AND COMPOSITIONS AND METHODS RELATED THERETO | H LUNDBECK AS (DK) | 2026-01-01 | — | — | US | claimed |
| WO-2025262247-A1 | TREATMENT OF HEADACHE DISORDERS AND/OR PSYCHIATRIC SYMPTOMS USING ANTI-CGRP ANTIBODIES, AND COMPOSITIONS AND METHODS RELATED THERETO | H. LUNDBECK A/S (DK) | 2025-12-26 | — | — | WO | claimed |
| US-20250367208-A1 | FORMULATIONS OF VILOXAZINE | SUPERNUS PHARMACEUTICALS, INC. (US) | 2025-12-04 | — | — | US | claimed |
| EP-4654949-A1 | USE OF VITAMIN E TPGS AS A TASTE MASKING AGENT FOR BITTER DRUGS | Hyloris Developments SA (BE) | 2025-12-03 | — | — | EP | claimed |
| WO-2025245322-A1 | OXYTOCIN-BASED THERAPEUTICS TO IMPROVE COGNITIVE CONTROL IN INDIVIDUALS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER | THE GENERAL HOSPITAL CORPORATION (US) | 2025-11-27 | — | — | WO | claimed |
| WO-2002041883-A2 | AS-NEEDED ADMINISTRATION OF TRICYCLIC AND OTHER NON-SRI ANTIDEPRESSANT DRUGS TO TREAT PREMATURE EJACULATION | VIVUS, INC. (US) | 2002-05-30 | — | — | WO | claimed |
| US-20020037828-A1 | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation | VIVUS, INC. | 2002-03-28 | — | — | US | claimed |
| US-20020010216-A1 | New drug combinations | PHARMACIA & UPJOHN COMPANY | 2002-01-24 | — | — | US | claimed |
| WO-2001062236-A2 | NEW DRUG COMBINATIONS COMPRISING A NOREPINEPHRINE REUPTAKE INHIBITOR AND AN ANTIMUSCARINIC AGENT | PHARMACIA & UPJOHN COMPANY (US) | 2001-08-30 | — | — | WO | claimed |
| US-20010008896-A1 | Administration of active agents, including 5-HT receptor agonists and antagonists, to treat premature ejaculation | SMITH WILLIAM L (US) | 2001-07-19 | — | — | US | claimed |
| WO-2001021190-A1 | TREATMENT FOR NARCOLEPSY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-03-29 | — | — | WO | claimed |
| US-6204245-B1 | Treatment of narcolepsy with immunosuppressants | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2001-03-20 | — | — | US | claimed |
| US-5922341-A | Local administration of pharmacologically active agents to treat premature ejaculation | VIVUS, INCORPORATED (US) | 1999-07-13 | — | — | US | claimed |
| WO-1997041878-A1 | TREATMENT OF MOOD DISORDERS WITH A GROWTH HORMONE SECRETAGOGUE | MERCK & CO., INC. (US) | 1997-11-13 | — | — | WO | claimed |
| EP-0089948-B1 | PHARMACEUTICAL COMPOSITIONS | COPPEN, Alec James (GB) | 1985-08-14 | — | — | EP | claimed |